Federated Hermes
TGTX icon

Federated Hermes’s TG Therapeutics TGTX Stock Holding History

Federated Hermes’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Buy
204,915
+177,325
+643% +$7.26M 0.02% 657
2026
Q1 		$917K Buy
+27,590
New +$822K ﹤0.01% 1141
2025
Q4 		– Sell
-11
Closed -$397 – 2199
2025
Q3 		$397 Sell
11
-125,037
-100% -$4.12M ﹤0.01% 2097
2025
Q2 		$4.5M Buy
125,048
+58,745
+89% +$2.19M 0.01% 750
2025
Q1 		$2.61M Sell
66,303
-64,385
-49% -$2.17M 0.01% 877
2024
Q4 		$3.93M Buy
130,688
+26,887
+26% +$772K 0.01% 765
2024
Q3 		$2.43M Buy
103,801
+103,751
+207,502% +$2.27M 0.01% 886
2024
Q2 		$890 Buy
+50
New +$798 ﹤0.01% 1953
2023
Q4 		– Sell
-55
Closed -$460 – 2204
2023
Q3 		$460 Sell
55
-135
-71% -$1.88K ﹤0.01% 2044
2023
Q2 		$4.72K Buy
190
+1
+0.5% +$26 ﹤0.01% 1907
2023
Q1 		$2.84K Sell
189
-396
-68% -$6.01K ﹤0.01% 1980
2022
Q4 		$6.92K Sell
585
-581,836
-100% -$4.22M ﹤0.01% 1904
2022
Q3 		$3.45M Sell
582,421
-1,652,558
-74% -$10.8M 0.01% 755
2022
Q2 		$9.5M Buy
2,234,979
+1,452,446
+186% +$9.07M 0.03% 556
2022
Q1 		$7.44M Buy
+782,533
New +$9.06M 0.02% 681
2021
Q1 		– Sell
-6,173
Closed -$321K – 2346
2020
Q4 		$321K Sell
6,173
-35,479
-85% -$1.2M ﹤0.01% 1621
2020
Q3 		$1.11M Sell
41,652
-356,356
-90% -$8.2M ﹤0.01% 1201
2020
Q2 		$7.75M Buy
398,008
+304,957
+328% +$4.91M 0.02% 607
2020
Q1 		$916K Buy
93,051
+92,851
+46,426% +$1.17M ﹤0.01% 1172
2019
Q4 		$2K Buy
+200
New +$1.52K ﹤0.01% 2044
2018
Q3 		– Sell
-74,643
Closed -$982K – 2324
2018
Q2 		$982K Buy
74,643
+17,104
+30% +$235K ﹤0.01% 1299
2018
Q1 		$817K Buy
+57,539
New +$735K ﹤0.01% 1281

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Federated Hermes's TGTX Position: Q2 2026 in Review

Federated Hermes increased its TG Therapeutics (TGTX) stake by 643% in Q2 2026, buying an estimated $7.26M and bringing the position to 204,915 shares worth $11.3M. The position accounts for 0.02% of the portfolio, ranked #657.

Federated Hermes first reported a position in TGTX in Q1 2018 and has held it in 22 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Federated Hermes held 204,915 shares of TG Therapeutics worth $11.3M as of Q2 2026.
  • Federated Hermes bought 177,325 TG Therapeutics shares in Q2 2026, an estimated $7.26M.
  • TG Therapeutics made up 0.02% of Federated Hermes's portfolio in Q2 2026, its #657 holding.
  • Federated Hermes first reported a position in TG Therapeutics in Q1 2018 and has held it in 22 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.